Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 9Myelodysplastic Syndromes 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Burkitt Lymphoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Lymphoma, Mantle-Cell 2Lymphoma 2Leukemia, Biphenotypic, Acute 2Smoldering Multiple Myeloma 1Primary Myelofibrosis 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Juvenile 1Leukemia 1Bone Marrow Neoplasms 1

Interventions

Lenalidomide 6carfilzomib 3Dexamethasone 3daratumumab 2Melphalan 2Leflunomide 2poly ICLC 1pembrolizumab 1isatuximab 1fludarabine phosphate 1fludarabine 1citarinostat 1Watchful Waiting 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1PVX-410 vaccine 1Observation 1Myelography 1Metformin 1Cyclophosphamide 1Cholestyramine Resin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Smoldering Multiple Myeloma × Stem Cell Transplantation × Clear all
NCT00114101 2026-05-29

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

National Cancer Institute (NCI)

Phase 3 Active not recruiting
460 enrolled 11 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡